/
/
Refractory Myeloma? PomCyDex May Be an Effective Oral Option
Refractory Myeloma? PomCyDex May Be an Effective Oral Option image
Refractory Myeloma? PomCyDex May Be an Effective Oral Option
Posted Mar 31, 2016

Pomalidomide plus cyclophosphamide and dexamethasone (PomCyDex) resulted in a higher overall response rate as compared with pomalidomide plus low-dose dexamethasone (PomDex) in patients with refractory multiple myeloma, a study published in the journal Blood has shown. Because PomDex is a standard treatment for patients refractory to Revlimid (lenalidomide) who have received three or more prior therapies, researchers sought to evaluate the safety and efficacy of adding oral weekly cyclophosphamide to PomDex in the refractory setting. In two different studies, in terms of safety, there was no significant increase in toxicity with the addition of cyclophosphamide compared with PomDex alone. Most treatment-related adverse events were hematological toxicities. The findings ultimately suggest that PomCyDex is an effective oral regimen for patients with refractory multiple myeloma. For more information on these studies and results, visit Cancer Therapy Advisor here.

Find All Refractory Myeloma Clinical Trials

SparkCures-200x50
The author Lizzy Smith

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811